Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient. / Doll, Sophia; Kriegmair, Maximilian C.; Santos, Alberto; Wierer, Michael; Coscia, Fabian; Neil, Helen Michele; Porubsky, Stefan; Geyer, Philipp E.; Mund, Andreas; Nuhn, Philipp; Mann, Matthias.

In: Molecular Oncology, Vol. 12, No. 8, 2018, p. 1296-1307.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Doll, S, Kriegmair, MC, Santos, A, Wierer, M, Coscia, F, Neil, HM, Porubsky, S, Geyer, PE, Mund, A, Nuhn, P & Mann, M 2018, 'Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient', Molecular Oncology, vol. 12, no. 8, pp. 1296-1307. https://doi.org/10.1002/1878-0261.12326

APA

Doll, S., Kriegmair, M. C., Santos, A., Wierer, M., Coscia, F., Neil, H. M., Porubsky, S., Geyer, P. E., Mund, A., Nuhn, P., & Mann, M. (2018). Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient. Molecular Oncology, 12(8), 1296-1307. https://doi.org/10.1002/1878-0261.12326

Vancouver

Doll S, Kriegmair MC, Santos A, Wierer M, Coscia F, Neil HM et al. Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient. Molecular Oncology. 2018;12(8):1296-1307. https://doi.org/10.1002/1878-0261.12326

Author

Doll, Sophia ; Kriegmair, Maximilian C. ; Santos, Alberto ; Wierer, Michael ; Coscia, Fabian ; Neil, Helen Michele ; Porubsky, Stefan ; Geyer, Philipp E. ; Mund, Andreas ; Nuhn, Philipp ; Mann, Matthias. / Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient. In: Molecular Oncology. 2018 ; Vol. 12, No. 8. pp. 1296-1307.

Bibtex

@article{20f8925e5a274ce2807f800163f3d584,
title = "Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient",
abstract = "Recent advances in mass spectrometry (MS)-based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition.",
keywords = "case study, clinical proteomics, epigenetics, mass spectrometry, urachal carcinoma",
author = "Sophia Doll and Kriegmair, {Maximilian C.} and Alberto Santos and Michael Wierer and Fabian Coscia and Neil, {Helen Michele} and Stefan Porubsky and Geyer, {Philipp E.} and Andreas Mund and Philipp Nuhn and Matthias Mann",
note = "{\textcopyright} 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.",
year = "2018",
doi = "10.1002/1878-0261.12326",
language = "English",
volume = "12",
pages = "1296--1307",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "8",

}

RIS

TY - JOUR

T1 - Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient

AU - Doll, Sophia

AU - Kriegmair, Maximilian C.

AU - Santos, Alberto

AU - Wierer, Michael

AU - Coscia, Fabian

AU - Neil, Helen Michele

AU - Porubsky, Stefan

AU - Geyer, Philipp E.

AU - Mund, Andreas

AU - Nuhn, Philipp

AU - Mann, Matthias

N1 - © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

PY - 2018

Y1 - 2018

N2 - Recent advances in mass spectrometry (MS)-based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition.

AB - Recent advances in mass spectrometry (MS)-based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition.

KW - case study

KW - clinical proteomics

KW - epigenetics

KW - mass spectrometry

KW - urachal carcinoma

U2 - 10.1002/1878-0261.12326

DO - 10.1002/1878-0261.12326

M3 - Journal article

C2 - 29901861

VL - 12

SP - 1296

EP - 1307

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 8

ER -

ID: 198265634